Preface -- Angiogenesis assays: an appraisal of current techniques -- Survey of pro-angiogenesis strategies -- Angiogenesis modulation by arachidonic acid – derived lipids: positive and negative regulators of angiogenesis -- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects -- Actions of steroids and peptide hormones on angiogenesis -- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.-  Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment -- Impact of nanotechnology on therapeutic angiogenesis -- Survey of anti-angiogenesis strategies -- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis -- Integrin antagonists and angiogenesis -- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology -- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration -- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit -- Biomarkers of response and resistance to anti-angiogenic treatment -- Speculations on new directions in which angiogenesis may proceed. Index.

 This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.